Search

Displaying results 2111 - 2120 of 8517 in total
  1. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. … Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)

  2. Drug

    Pseudoephedrine

    go.drugbank.com/drugs/DB00852
    Approved

    [A188823] The decongestant effect of pseudoephedrine was described in dogs in 1927.[A188823]

    Mixtures: NOXIN D JARABE
  3. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    Bethanechol is a synthetic ester that was initially synthesized in 1935. … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous

  4. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]

  5. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  6. Drug

    Estazolam

    go.drugbank.com/drugs/DB01215
    ApprovedIllicitInvestigational

    It has been shown in some cases to be more potent than diazepam or nitrazepam.

  7. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing … Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label].

  8. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  9. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.

  10. Drug

    BMS-488043

    go.drugbank.com/drugs/DB05532
    Experimental

    BMS-488043 has been investigated as an anti-HIV agent.